Complex laboratory-instrumental and prognostic assessment in hypertensive patients with type 2 diabetes mellitus and atrial fibrillation

Objective. To perform a complex laboratory and instrumental and prognostic assessment of hypertensive subjects with type 2 diabetes mellitus (DM) and atrial fibrillation (AF). Design and methods. Based on the retrospective analysis out of 3150 case records we selected 443 clinical cases of arterial hypertension combined with type 2 diabetes mellitus (DM 2) and with or without atrial fibrillation (AF). They were divided into groups: 1st group included hypertensive patients with DM 2 and AF; 2nd — hypertensives with DM 2, and third — hypertensives with AF. We analyzed haemodynamic, electro-and echocardiography, routine biochemical (blood sugar, glycated hemoglobin, uric acid, potassium, microalbuminuria, cholesterol, low and high density lipoproteins, triglyceride, prothrombin and international normalized ratio, C-reactive protein) parameters, as well as adipokine levels (tumor necrosis factor alpha, adiponectine, leptine, resistine). Kaplan-Meyer’s analysis was performed to assess survival rate. Results. Patients from the 1st group showed subclinical target organ damage, dysregulation of metabolism and hormonal and regulatory activity. Compared to other groups these patients demonstrated a lower survival rate. Conclusion. The association of arterial hypertension, DM 2 and AF can be considered as a mutual burdening phenomenon, increasing the cardiovascular risk.

arterial hypertension, type 2 diabetes mellitus, atrial fibrillation, adipokines, survival rate

1. Kannel W., Wolf P., Benjamin E., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates // Am. J. Cardiol. — 1998. — Vol. 82, № 8A. — P. 2N-9N.

2. Movahed M., Hashemzadeh M., Jamal M. Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus // Heart Vessels. — 2007. — Vol. 22, № 4. — P. 251-253.

3. Aksnes T., Schmieder R., Kjeldsen S. et al. Impact of new and onset diabetes mellitus on development of atrial fibrillation and heart failure in high risk hypertension (from the VALUE Trial) // Am. J. Cardiol. — 2008. — Vol. 101, № 5. — P. 634-638.

4. Kannel W., Benjamin W. Status of the epidemiology of atrial fibrillation // Med. Clin. North. Am. — 2008. — Vol. 92, № 1. — P. 17-40.

5. Heeringa J., van der Kuip D.A., Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study // Eur. Heart J. — 2006. — Vol. 27, № 8. — P. 949-953.

6. Mancia G., De Backer G., Dominiczak A. et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. — 2007. — Vol. 28, № 12. — P. 1105-1187.

7. Levitan E., Song Y., Ford E. et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies // Arch. Intern. Med. — 2004. — Vol. 164, №19. — P. 2147-2155.

8. Ye X., Yu Z., Li H., Franco O.H., Liu Y., Lin X. Distributions of C-reactive protein and its association with metabolic syndrome in middleaged and older Chinese people // J. Am. Coll. Cardiol. — 2007. — Vol. 49, № 17. — P. 1798-1805.

9. Vranic M. Odyssey between Scylla and Charibdis through storms of carbohydrate metabolism and diabetes: a career retrospective // Am. J. Physiol. Endocrinol. Metab. 2010. — Vol. 299, № 6. — Р. E849-E867.

10. Барсуков А.В., Свеклина T.C., Таланцева М.С., Шустов С.Б. Артериальная гипертензия, сахарный диабет 2 типа и фибрилляция предсердий как самостоятельная медицинская проблема // Артериальн. гипертензия. — 2011. — Т. 17, № 2. — С. 108-114.